Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: Implications for perioperative anti-FGFR3 treatment

D. Pouessel, Y. Neuzillet, L. S. Mertens, M. S. van der Heijden, J. de Jong, J. Sanders, D. Peters, K. Leroy, A. Manceau, P. Maille, P. Soyeux, A. Moktefi, F. Semprez, D. Vordos, A. de la Taille, C. D. Hurst, D. C. Tomlinson, P. Harnden, P. J. Bostrom, T. MirttiS. Horenblas, Y. Loriot, N. Houédé, C. Chevreau, P. Beuzeboc, S. F. Shariat, Arthur I Sagalowsky, R. Ashfaq, M. Burger, M. A S Jewett, A. R. Zlotta, A. Broeks, B. Bapat, M. A. Knowles, Yair Lotan, T. H. van der Kwast, S. Culine, Y. Allory, B. W G Van Rhijn

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint Dive into the research topics of 'Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: Implications for perioperative anti-FGFR3 treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences